Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 151 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: HDL Clear all

Conditions: Antioxidant Absorption
Interventions: Obicetrapib 10mg, Placebo; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami Gardens, Florida

Conditions: Dyslipidemia
Interventions: JTT-302; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Santa Ana, California

Conditions: Pain, Pain, Chronic
Interventions: Pain Evaluation and BPISF, Surveys, a fingerstick blood sample, EMAs, and a digital wearable device; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 4
States / cities: New York, New York

Conditions: Lipoprotein Metabolism, PCSK9, Proteomics
Interventions: EPA-rich fish oil, DHA-rich fish oil; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 80
States / cities: Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more

Conditions: Hypertriglyceridemia, Cardiovascular Disease
Interventions: Olive oil, 4g, omega-3-carboxylic acids, 2g, omega-3-carboxylic acids, 4g; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 89
States / cities: Muscle Shoals, Alabama • Chandler, Arizona • Phoenix, Arizona + 78 more

Conditions: Cardiovascular Disease, Diabetes, Dyslipidemia
Interventions: Man-made Trans FA, Natural Trans FA, Oleic Acid; Dietary Supplement
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Oakland, California

Conditions: Inflammation, Atherosclerosis, Cardiovascular Disease
Interventions: PolyResveratrol Supplementation, Curcumin Supplementation; Dietary Supplement
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Epic Research & Diagnostics, Inc.; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 193 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Scottsdale, Arizona

Conditions: Dyslipidemia
Interventions: Alirocumab, Statins, Ezetimibe, Fenofibrate, Nicotinic acid, Omega-3 fatty acids, Antihyperglycemic Drug; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 57
States / cities: Little Rock, Arkansas • Fresno, California • Huntington Beach, California + 51 more

Conditions: HIV Infections
Interventions: ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HDL, Health, Subjective
Interventions: Dietary supplementation; Dietary Supplement
Lead sponsor: Metagenics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome
Interventions: Questionnaires, Laboratory tests, Abdominal MRI; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis
Interventions: CP-690,550 (tasocitinib); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: Anniston, Alabama • Little Rock, Arkansas • Los Angeles, California + 5 more

Conditions: Type1 Diabetes Mellitus, Diabetes Mellitus, Type 1, Autoimmune Diabetes, Juvenile Diabetes, Diabetes Mellitus Complication, Diabetic Nephropathies, Metabolic Disease, Diabetic Kidney Disease
Interventions: Blood draw, Urine sample collection, DXA scan; Diagnostic Test
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 7 Years to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Quercetin, Lipid Metabolism, Aging
Interventions: Quercetin Phytosome; Dietary Supplement
Lead sponsor: Thorne HealthTech, Inc; Industry
Eligibility: 20 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Summerville, South Carolina

Conditions: Dyslipidemia
Interventions: LCP-AtorFen, atorvastatin, fenofibrate; Drug
Lead sponsor: Veloxis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metabolic Syndrome
Interventions: Resveratrol, Placebo; Dietary Supplement
Lead sponsor: Vanderbilt University; Other
Eligibility: 30 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Nashville, Tennessee • Houston, Texas

Conditions: Overweight, Cardiovascular Diseases
Interventions: Low Fat and High Carbohydrate Diet, High Fat and Low Carbohydrate Diet; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Coronary Syndromes
Interventions: CER-001, Placebo; Drug
Lead sponsor: Cerenis Therapeutics, SA; Industry
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 13
States / cities: Huntsville, Alabama • San Diego, California • Torrance, California + 9 more

Conditions: Cardiovascular Disease
Interventions: Placebo, Alpha cyclodextrin; Other · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heart Health Screening and Prevention
Interventions: Fingerstick cholesterol test, Atherosclerosis Cardiovascular Disease Risk assessment, Blood pressure measurement; Procedure · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Dyslipidemia
Interventions: LCP-AtorFen; Drug
Lead sponsor: Veloxis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cardiovascular Outcomes
Interventions: Niaspan, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers

Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Chronic Pain Diagnosis and Treatment in Torture Survivors

Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL

The Effects of Natural Versus Man-Made Trans Fatty Acids on Lipoprotein Profiles: A Pilot Study

Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL

Metabolic Syndrome Feasibility Study

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

HIV Antiretroviral Drugs and Metabolism

HDL Function Dietary Supplement Safety and QOL

Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant

Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus

Effects of Quercetin on Metabolic Health

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

Resveratrol in Metabolic Syndrome: Effect on Platelet Hyper-reactivity and HDL Lipid Peroxidation

Dietary Fat and High-Density Lipoprotein (HDL) Metabolism-Effect of Carbohydrate and Fat Intake

CER-001 Atherosclerosis Regression ACS Trial

Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol

Beauty from Within Community Screening Project

12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia

Benefit of Elevation of HDL-C in Women